Natasha is an Associate Professor in the Division of Infectious Diseases and Global Public Health in the Department of Medicine at the University of California San Diego. She is also an Honorary Senior Lecturer at the University of Bristol. Dr. Martin is an infectious disease modeler whose work evaluates the impact and cost-effectiveness of viral hepatitis and HIV prevention interventions among high risk populations such as people who inject drugs, men who have sex with men, and incarcerated populations. She is one of the leading modelers examining the potential impact of HCV treatment as prevention, and what prevention scale-up is is required for HCV elimination. In 2016, she was selected by The Economist magazine as a “HCV Change Maker”, providing “fresh thinking on the road to elimination of HCV.”

Chris Gough is Executive Director of the Canberra Alliance for Harm Minimisation and Advocacy (CAHMA) and The Connection health service. He identifies as a person who uses drugs and a consumer of BBV and ATOD services. Chris’ expertise centres around peer and consumer driven programming including peer education, peer treatment support, community development, consumer representation and advocacy.

Behzad is a clinical epidemiologist, and a Senior Lecturer in the Kirby Institute (UNSW Sydney). He trained as a Medical Practitioner and has a PhD in Medicine. His main areas of research include epidemiology and clinical management of viral hepatitis, particularly in prison, and among people who inject drugs.

Alexander Thompson is the Professor-Director of Gastroenterology at St. Vincent’s Hospital Melbourne and Professorial Fellow of the University of Melbourne. Alexander is also Program Director for the Victorian Statewide Hepatitis Service, Australia.